Home > Boards > US Listed > Medical - Drugs > Revive Therapeutics Ltd. (RVVTF)

June 2020

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Fress Member Profile
Followed By 43
Posts 1,300
Boards Moderated 0
Alias Born 02/10/17
160x600 placeholder
Fress   Thursday, 07/09/20 07:56:35 AM
Re: None
Post # of 8442 
June 2020
Revive Therapeutics: Video Analyst explains in the link below & sees 'substantial upside potential' as key assets move towards clinic.

Near term catalyst:
1.FDA signing off on Phase 3 Trial can happen any day for Bucillamine
2.Asia updates on trials for Covid-19 Bucillamine
3.Canadian updates on Covid-19 Bucillamine
4.Patent News Updates
5.Partership for Trials
6.Government Funding
7. Buyout Approval could be Billions in revenue for a big biotech company
8.Manufacturing deal Atwill Medical Solutions CEO is on the Revive board just signed a deal with VXRT
Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP?William Jackson, Director on Revive board


RVVTF funded through 2021

1.OTC stock CYDY .26-$10.00 this year 3 Billion market cap Phase for Covid-19
2.VXRT .25-$14.00+ preclinical Covid-19 800 million market cap
3.RVVTF 30 Million market cap Phase 3 is very close.

3 year hit last week .50

All time high of .55 will be taken out sooner than later.

Dollars on positive top line results during its Phase 3 Trials.
$10.00-$20.00+ on Approval by end of 2020

from the companies presentation June 2020 Page 12

Q4 Initial results from Phase 3 clinical study of Bucillamine in the treatment of COVID-19

Revive therapeutics Company Presentation Summer 2020


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist